This study quantifies the increased prevalence of and additional medical costs associated with related comorbidities in patients with OAB, emphasizing that the economic and clinical impact of OAB extends beyond the disease itself. Thus, management of patients with OAB should be of greater focus with both clinicians and health care payers.

Patients newly prescribed venlafaxine XR were at least 3 times more likely to achieve treatment adequacy for 84 and 180 days compared with those newly prescribed fluoxetine. Treatment adequacy as a proxy for optimal treatment may be an important factor to consider when selecting an antidepressant drug.

No abstract